1752-1753 / 2437
RT/TMZ
TMZ + marizomib in newly diagnosed glioblastoma
EOC 1 EOC 2
EOC 3
EOC 4
EOC 5
*
Expansion Start
Expansion
Complete
0
10
20
30
40
50
60
Jun-2016
Jul-2016
Aug-2016
Sep-2016
Oct-2016
Nov-2016
Dec-2016
Jan-2017
Feb-2017
Mar-2017
Apr-2017
May-2017
Jun-2017
Jul-2017
Aug-2017
Sep-2017
Oct-2017
Nov-2017
Dec-2017
Jan-2018
Feb-2018
Mar-2018
Apr-2018
May-2018
Jun-2018
Jul-2018
Patients (total)
Concomitant
Adjuvant
Expansion
CONCOMITANT TREATMENT (MRZ+RT+TMZ 6 wks, BREAK 4 wks)
Cohort
Dose
(mg/m
2
)
N*
Safety
Evaluation
Timing – First Pt Dose to
Safety Evaluation
1
0.55
3
8 wks
14 wks
2
0.7
3
8 wks
14 wks
3
0.8
3
8 wks
14 wks
4
1.0
**
3
8 wks
14 wks
5
1.2
3
8 wks
14 wks
ADJUVANT TREATMENT (MRZ+TMZ 28-day cycle)
Cohort
Dose
(mg/m
2
)
N
Safety
Evaluation
Timing – First Pt Dose to
Safety Evaluation
1
0.55
3
4 wks
10 wks
2
0.7
3
4 wks
10 wks
3
0.8
3
4 wks
10 wks
4
1.0
**
3
4 wks
10 wks
5
1.2
3
4 wks
10 wks